Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase II Study of Pembrolizumab (MK-3475) in Patients With Advanced Small Bowel Adenocarcinomas

NCT02949219 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT02949219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02949219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase II Study of Pembrolizumab (MK-3475) in Patients With Advanced Small Bowel Adenocarcinomas
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 2
Overall status
Unknown status
Start date
March 24, 2017
Completion date
December 31, 2024
Enrollment
41 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic small intestinal adenocarcinoma, recurrent small intestinal carcinoma, unresectable small intestinal carcinoma